Globenewswire·2025-10-05 17:59Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations, which could negatively impact the clinical and commercial prospects of its products, including briquilimab [5]. - The failure to disclose these issues increased the risk of confounding study results and the likelihood of disruptive cost-reduction measures, leading to an overstatement of Jasper's business and financial prospects [5].